current preference remains with use of single-agent osimertinib with or without chemotherapy or with combination bispecific antibody and lazertinib TKI in the management of advanced NSCLC.

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

The study represents the largest dataset of HER2-mutated NSCLC patients treated with a TKI, offering a new oral treatment option with limited toxicity. Results could give patients with HER2 ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and ...

Around 70% of NSCLC patients are diagnosed at locally advanced ... Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights. It has been approved by the China's ...